Table 1

Clinical data of study patients

Δ thrombus score ≥4 (n = 26)Δ thrombus score <4 (n = 22)
Patient characteristics   
 Male (%) 46.2% 45.5% 
 Age (years ± SD) 68 (±9) 68 (±11) 
 Current smoker (%) 15.4% 13.6% 
 Body mass index (±SD) 28.5 (±2) 31.7 (±2) 
 Immobilization/surgery (%) 15.4% 18.2% 
 Malignancy (%) 23.1% 31.8% 
 Thrombophilia (%) 0% 4.5% 
 Previous VTE (%) 42.3% 36.4% 
 PTS 12 mo after diagnosis (%) 16.7% 50% 
 Median Villalta score (score; percentile 25/75) 2.5 (2.0/4.0) 4.5 (2.0/7.0) 
Treatments   
 Duration of anticoagulation (%)   
  3 to 6 mo 0% 9.1% 
  6 to 12 mo 15.4% 22.7% 
  >12 mo 84.6% 68.2% 
 Vitamin K antagonists (%)* 69.2% 72.7% 
 Therapeutic dosage of low molecular weight heparin (%)* 26.9% 27.3% 
 Dabigatran (%)* 3.9% 0% 
D-Dimer and sPECAM-1   
 Median D-Dimer baseline (μg/mL; percentile 25/75) 4.5 (3.1/11.0) 3.3 (2.1/4.4) 
 Median D-Dimer d 28 (±3) (μg/mL; percentile 25/75) 1.2 (0.7/1.5) 0.7 (0.5/1.5) 
 Median sPECAM-1 baseline (ng/mL; percentile 25/75) 71.54 (51.05/81.04) 92.50 (87.73/103.36)  
 Median sPECAM-1 d 28 (±3) (ng/mL; percentile 25/75) 71.96 (57.22/87.03) 90.07 (73.02/102.62) 
Thrombus burden   
 Mean thrombus score baseline (±SD) 16.7 (±9.1) 10.5 (±2.0) 
 Mean thrombus score d 28 (±3) (±SD) 10.0 (±9.1) 10.3 (±2.5) 
 Mean Δ thrombus score (±SD) 6.7 (±2.5) .3 (±2.4)  
 Proximal segment baseline (%)   
  Popliteal vein 11.5% 9.1% 
  Distal femoral vein 19.2% 18.2% 
  Femoral vein (mid-segment) 30.8% 36.4% 
  Proximal femoral vein 30.8% 36.4% 
  External iliac vein 7.6% 0% 
Δ thrombus score ≥4 (n = 26)Δ thrombus score <4 (n = 22)
Patient characteristics   
 Male (%) 46.2% 45.5% 
 Age (years ± SD) 68 (±9) 68 (±11) 
 Current smoker (%) 15.4% 13.6% 
 Body mass index (±SD) 28.5 (±2) 31.7 (±2) 
 Immobilization/surgery (%) 15.4% 18.2% 
 Malignancy (%) 23.1% 31.8% 
 Thrombophilia (%) 0% 4.5% 
 Previous VTE (%) 42.3% 36.4% 
 PTS 12 mo after diagnosis (%) 16.7% 50% 
 Median Villalta score (score; percentile 25/75) 2.5 (2.0/4.0) 4.5 (2.0/7.0) 
Treatments   
 Duration of anticoagulation (%)   
  3 to 6 mo 0% 9.1% 
  6 to 12 mo 15.4% 22.7% 
  >12 mo 84.6% 68.2% 
 Vitamin K antagonists (%)* 69.2% 72.7% 
 Therapeutic dosage of low molecular weight heparin (%)* 26.9% 27.3% 
 Dabigatran (%)* 3.9% 0% 
D-Dimer and sPECAM-1   
 Median D-Dimer baseline (μg/mL; percentile 25/75) 4.5 (3.1/11.0) 3.3 (2.1/4.4) 
 Median D-Dimer d 28 (±3) (μg/mL; percentile 25/75) 1.2 (0.7/1.5) 0.7 (0.5/1.5) 
 Median sPECAM-1 baseline (ng/mL; percentile 25/75) 71.54 (51.05/81.04) 92.50 (87.73/103.36)  
 Median sPECAM-1 d 28 (±3) (ng/mL; percentile 25/75) 71.96 (57.22/87.03) 90.07 (73.02/102.62) 
Thrombus burden   
 Mean thrombus score baseline (±SD) 16.7 (±9.1) 10.5 (±2.0) 
 Mean thrombus score d 28 (±3) (±SD) 10.0 (±9.1) 10.3 (±2.5) 
 Mean Δ thrombus score (±SD) 6.7 (±2.5) .3 (±2.4)  
 Proximal segment baseline (%)   
  Popliteal vein 11.5% 9.1% 
  Distal femoral vein 19.2% 18.2% 
  Femoral vein (mid-segment) 30.8% 36.4% 
  Proximal femoral vein 30.8% 36.4% 
  External iliac vein 7.6% 0% 

Patient characteristics, treatments, laboratory findings, and thrombus burden of patients with normal (Δ thrombus score ≥4) and delayed thrombus resolution (Δ thrombus score <4) at baseline, after 28 (±3) days and 12 (±0.5) months after DVT diagnosis are shown.

SD, standard deviation.

*

Pharmacological substance was evaluated 28 (±3) d after diagnosis.

P < .05.

P < .01.

or Create an Account

Close Modal
Close Modal